What Century Therapeutics, Inc. does.

We are a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Our beta islet, T cell and NK cell programs are allogeneic, meaning they are derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. As a result, we believe such “off-the-shelf" therapies have the potential to overcome the limitations of first-generation cell therapies by providing readily available treatments more quickly, reliably, at greater scale, and to a broader patient population. What we believe further sets us apart from other allogeneic approaches is our focus on induced pluripotent stem cells, or iPSCs, which possess the unique ability to self-renew indefinitely and differentiate into any cell type, enabling virtually unlimited genetic editing, consistent reproducibility, and scalable manufacturing. We have created a comprehensive, genetically engineered allogeneic cell therapy platform that includes:

● Industry-leading iPSCs and differentiation know-how to generate fully functional mature cells from iPSCs, or iPSC-derived cells;

Revenue and profit, by fiscal year.

More on IPSC.

• Century Therapeutics, Inc. summary
• Century Therapeutics, Inc. financial statements
• Century Therapeutics, Inc. key metrics
• Century Therapeutics, Inc. health scores and style box
• Century Therapeutics, Inc. earnings
• Century Therapeutics, Inc. dividends
• Century Therapeutics, Inc. valuation
• Century Therapeutics, Inc. ownership and insiders
• Century Therapeutics, Inc. peers

Figures from Century Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.